This is an extension study of HCV-05-002. The objective of this study is to evaluate the safety and efficacy of celgosivir plus peginterferon alfa-2b, with or without ribavirin, for an additional 36 weeks in patients with chronic hepatitis C genotype 1 infection.

Inclusion Criteria:

• Patients who completed HCV-05-002 only
• 18-65 years of age, inclusive
• Primary diagnosis of chronic HCV infection
• Non-responders to previous pegylated interferon-based therapy

Exclusion Criteria:

• Patients naive to interferon-based therapy for chronic HCV infection